Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pharvaris N.V. before investing.

In this article, we go over a few key elements for understanding Pharvaris N.V.’s stock price such as:

• Pharvaris N.V.’s current stock price and volume
• Why Pharvaris N.V.’s stock price changed recently
• Upgrades and downgrades for PHVS from analysts
• PHVS’s stock price momentum as measured by its relative strength

About Pharvaris N.V. (PHVS)

Before we jump into Pharvaris N.V.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Want to learn more about Pharvaris N.V.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Pharvaris N.V..

What Caused Pharvaris N.V. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of October 30, 2026, there were 0 analysts who downgraded Pharvaris N.V.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Pharvaris N.V.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Pharvaris N.V.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Pharvaris N.V. (PHVS) by visiting AAII Stock Evaluator.

Relative Price Strength of Pharvaris N.V.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of October 30, 2026, Pharvaris N.V. has a weighted four-quarter relative price strength of 6.84%, which translates to a Momentum Score of 78 and is considered to be Strong.

Want to learn more about how Pharvaris N.V. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Pharvaris N.V. Stock Price: Bottom Line

As of November 2, 2026, Pharvaris N.V.’s stock price is $33.595, which is up 0.19% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Pharvaris N.V. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.